Replication study of plasma proteins relating to Alzheimer's pathology

Liu Shi; Laura M. Winchester; Sarah Westwood; Alison L. Baird; Sneha N. Anand; Noel J. Buckley; Abdul Hye; Nicholas J. Ashton; Isabelle Bos; Stephanie J.B. Vos; Mara ten Kate; Philip Scheltens; Charlotte E. Teunissen; Rik Vandenberghe; Silvy Gabel; Karen Meersmans; Sebastiaan Engelborghs; Ellen E. De Roeck; Kristel Sleegers; Giovanni B. Frisoni; Olivier Blin; Jill C. Richardson; Régis Bordet; José L. Molinuevo; Lorena Rami; Anders Wallin; Petronella Kettunen; Magda Tsolaki; Frans Verhey; Alberto Lléo; Isabel Sala; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Peter Johannsen; Yvonne Freund-Levi; Lutz Frölich; Valerija Dobricic; Cristina Legido-Quigley; Frederik Barkhof; Ulf Andreasson; Kaj Blennow; Henrik Zetterberg; Johannes Streffer; Christina M. Lill; Lars Bertram; Pieter Jelle Visser; Hartmuth C. Kolb; Vaibhav A. Narayan; Simon Lovestone; Alejo J. Nevado-Holgado

doi:10.1002/alz.12322

Replication study of plasma proteins relating to Alzheimer's pathology

Liu Shi^*, Laura M. Winchester, Sarah Westwood, Alison L. Baird, Sneha N. Anand, Noel J. Buckley, Abdul Hye, Nicholas J. Ashton, Isabelle Bos, Stephanie J.B. Vos, Mara ten Kate, Philip Scheltens, Charlotte E. Teunissen, Rik Vandenberghe, Silvy Gabel, Karen Meersmans, Sebastiaan Engelborghs, Ellen E. De Roeck, Kristel Sleegers, Giovanni B. FrisoniOlivier Blin, Jill C. Richardson, Régis Bordet, José L. Molinuevo, Lorena Rami, Anders Wallin, Petronella Kettunen, Magda Tsolaki, Frans Verhey, Alberto Lléo, Isabel Sala, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Peter Johannsen, Yvonne Freund-Levi, Lutz Frölich, Valerija Dobricic, Cristina Legido-Quigley, Frederik Barkhof, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Johannes Streffer, Christina M. Lill, Lars Bertram, Pieter Jelle Visser, Hartmuth C. Kolb, Vaibhav A. Narayan, Simon Lovestone, Alejo J. Nevado-Holgado

^*Corresponding author for this work

17 Citations (Scopus)

Abstract

Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the “ATN” (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. Methods: Plasma proteins from 972 subjects (372 controls, 409 mild cognitive impairment [MCI], and 191 AD) were measured using both SOMAscan and targeted assays, including 4001 and 25 proteins, respectively. Results: Protein co-expression network analysis of SOMAscan data revealed the relation between proteins and “N” varied across different neurodegeneration markers, indicating that the ATN variants are not interchangeable. Using hub proteins, age, and apolipoprotein E ε4 genotype discriminated AD from controls with an area under the curve (AUC) of 0.81 and MCI convertors from non-convertors with an AUC of 0.74. Targeted assays replicated the relation of four proteins with the ATN framework and clinical diagnosis. Discussion: Our study suggests that blood proteins can predict the presence of AD pathology as measured in the ATN framework as well as clinical diagnosis.

Original language	English
Journal	Alzheimer's and Dementia
Volume	17
Issue number	9
Pages (from-to)	1452-1464
Number of pages	13
ISSN	1552-5260
DOIs	https://doi.org/10.1002/alz.12322
Publication status	Published - 09.2021

Funding

This research was conducted as part of the EMIF-AD MBD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n? 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies? in-kind contribution. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the 5th framework program (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007, and #15005). RV is a senior clinical investigator of the Flemish Research Foundation (FWO). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). We acknowledge the contribution of the personnel of the Genomic Service Facility at the VIB-U Antwerp Center for Molecular Neurology. The research at VIB-CMN is funded in part by the University of Antwerp Research Fund. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); and the UK Dementia Research Institute at UCL. FB is supported by the NIHR biomedical research center at UCLH.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Medical Genetics

DFG Research Classification Scheme

2.23-07 Clinical Neurology, Neurosurgery and Neuroradiology

Access to Document

10.1002/alz.12322

Cite this

Shi, L., Winchester, L. M., Westwood, S., Baird, A. L., Anand, S. N., Buckley, N. J., Hye, A., Ashton, N. J., Bos, I., Vos, S. J. B., Kate, M. T., Scheltens, P., Teunissen, C. E., Vandenberghe, R., Gabel, S., Meersmans, K., Engelborghs, S., De Roeck, E. E., Sleegers, K., ... Nevado-Holgado, A. J. (2021). Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 17(9), 1452-1464. https://doi.org/10.1002/alz.12322

@article{6e608afc921c4941b82755497be5f40e,

title = "Replication study of plasma proteins relating to Alzheimer's pathology",

abstract = "Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the “ATN” (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. Methods: Plasma proteins from 972 subjects (372 controls, 409 mild cognitive impairment [MCI], and 191 AD) were measured using both SOMAscan and targeted assays, including 4001 and 25 proteins, respectively. Results: Protein co-expression network analysis of SOMAscan data revealed the relation between proteins and “N” varied across different neurodegeneration markers, indicating that the ATN variants are not interchangeable. Using hub proteins, age, and apolipoprotein E ε4 genotype discriminated AD from controls with an area under the curve (AUC) of 0.81 and MCI convertors from non-convertors with an AUC of 0.74. Targeted assays replicated the relation of four proteins with the ATN framework and clinical diagnosis. Discussion: Our study suggests that blood proteins can predict the presence of AD pathology as measured in the ATN framework as well as clinical diagnosis.",

author = "Liu Shi and Winchester, \{Laura M.\} and Sarah Westwood and Baird, \{Alison L.\} and Anand, \{Sneha N.\} and Buckley, \{Noel J.\} and Abdul Hye and Ashton, \{Nicholas J.\} and Isabelle Bos and Vos, \{Stephanie J.B.\} and Kate, \{Mara ten\} and Philip Scheltens and Teunissen, \{Charlotte E.\} and Rik Vandenberghe and Silvy Gabel and Karen Meersmans and Sebastiaan Engelborghs and \{De Roeck\}, \{Ellen E.\} and Kristel Sleegers and Frisoni, \{Giovanni B.\} and Olivier Blin and Richardson, \{Jill C.\} and R{\'e}gis Bordet and Molinuevo, \{Jos{\'e} L.\} and Lorena Rami and Anders Wallin and Petronella Kettunen and Magda Tsolaki and Frans Verhey and Alberto Ll{\'e}o and Isabel Sala and Julius Popp and Gwendoline Peyratout and Pablo Martinez-Lage and Mikel Tainta and Peter Johannsen and Yvonne Freund-Levi and Lutz Fr{\"o}lich and Valerija Dobricic and Cristina Legido-Quigley and Frederik Barkhof and Ulf Andreasson and Kaj Blennow and Henrik Zetterberg and Johannes Streffer and Lill, \{Christina M.\} and Lars Bertram and Visser, \{Pieter Jelle\} and Kolb, \{Hartmuth C.\} and Narayan, \{Vaibhav A.\} and Simon Lovestone and Nevado-Holgado, \{Alejo J.\}",

note = "Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",

year = "2021",

month = sep,

doi = "10.1002/alz.12322",

language = "English",

volume = "17",

pages = "1452--1464",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc",

number = "9",

}

Shi, L, Winchester, LM, Westwood, S, Baird, AL, Anand, SN, Buckley, NJ, Hye, A, Ashton, NJ, Bos, I, Vos, SJB, Kate, MT, Scheltens, P, Teunissen, CE, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, De Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, R, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lléo, A, Sala, I, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Freund-Levi, Y, Frölich, L, Dobricic, V, Legido-Quigley, C, Barkhof, F, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Lill, CM, Bertram, L, Visser, PJ, Kolb, HC, Narayan, VA, Lovestone, S & Nevado-Holgado, AJ 2021, 'Replication study of plasma proteins relating to Alzheimer's pathology', Alzheimer's and Dementia, vol. 17, no. 9, pp. 1452-1464. https://doi.org/10.1002/alz.12322

TY - JOUR

T1 - Replication study of plasma proteins relating to Alzheimer's pathology

AU - Shi, Liu

AU - Winchester, Laura M.

AU - Westwood, Sarah

AU - Baird, Alison L.

AU - Anand, Sneha N.

AU - Buckley, Noel J.

AU - Hye, Abdul

AU - Ashton, Nicholas J.

AU - Bos, Isabelle

AU - Vos, Stephanie J.B.

AU - Kate, Mara ten

AU - Scheltens, Philip

AU - Teunissen, Charlotte E.

AU - Vandenberghe, Rik

AU - Gabel, Silvy

AU - Meersmans, Karen

AU - Engelborghs, Sebastiaan

AU - De Roeck, Ellen E.

AU - Sleegers, Kristel

AU - Frisoni, Giovanni B.

AU - Blin, Olivier

AU - Richardson, Jill C.

AU - Bordet, Régis

AU - Molinuevo, José L.

AU - Rami, Lorena

AU - Wallin, Anders

AU - Kettunen, Petronella

AU - Tsolaki, Magda

AU - Verhey, Frans

AU - Lléo, Alberto

AU - Sala, Isabel

AU - Popp, Julius

AU - Peyratout, Gwendoline

AU - Martinez-Lage, Pablo

AU - Tainta, Mikel

AU - Johannsen, Peter

AU - Freund-Levi, Yvonne

AU - Frölich, Lutz

AU - Dobricic, Valerija

AU - Legido-Quigley, Cristina

AU - Barkhof, Frederik

AU - Andreasson, Ulf

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Streffer, Johannes

AU - Lill, Christina M.

AU - Bertram, Lars

AU - Visser, Pieter Jelle

AU - Kolb, Hartmuth C.

AU - Narayan, Vaibhav A.

AU - Lovestone, Simon

AU - Nevado-Holgado, Alejo J.

PY - 2021/9

Y1 - 2021/9

N2 - Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the “ATN” (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. Methods: Plasma proteins from 972 subjects (372 controls, 409 mild cognitive impairment [MCI], and 191 AD) were measured using both SOMAscan and targeted assays, including 4001 and 25 proteins, respectively. Results: Protein co-expression network analysis of SOMAscan data revealed the relation between proteins and “N” varied across different neurodegeneration markers, indicating that the ATN variants are not interchangeable. Using hub proteins, age, and apolipoprotein E ε4 genotype discriminated AD from controls with an area under the curve (AUC) of 0.81 and MCI convertors from non-convertors with an AUC of 0.74. Targeted assays replicated the relation of four proteins with the ATN framework and clinical diagnosis. Discussion: Our study suggests that blood proteins can predict the presence of AD pathology as measured in the ATN framework as well as clinical diagnosis.

AB - Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the “ATN” (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. Methods: Plasma proteins from 972 subjects (372 controls, 409 mild cognitive impairment [MCI], and 191 AD) were measured using both SOMAscan and targeted assays, including 4001 and 25 proteins, respectively. Results: Protein co-expression network analysis of SOMAscan data revealed the relation between proteins and “N” varied across different neurodegeneration markers, indicating that the ATN variants are not interchangeable. Using hub proteins, age, and apolipoprotein E ε4 genotype discriminated AD from controls with an area under the curve (AUC) of 0.81 and MCI convertors from non-convertors with an AUC of 0.74. Targeted assays replicated the relation of four proteins with the ATN framework and clinical diagnosis. Discussion: Our study suggests that blood proteins can predict the presence of AD pathology as measured in the ATN framework as well as clinical diagnosis.

UR - https://www.scopus.com/pages/publications/85103432126

UR - https://www.mendeley.com/catalogue/8202da8c-1dda-391c-b432-6e676fcc73fd/

U2 - 10.1002/alz.12322

DO - 10.1002/alz.12322

M3 - Journal articles

AN - SCOPUS:85103432126

SN - 1552-5260

VL - 17

SP - 1452

EP - 1464

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 9

ER -

Replication study of plasma proteins relating to Alzheimer's pathology

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Cite this